Cargando…

Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan

PURPOSE: Golimumab (GLM) is an anti-tumor necrosis factor (TNF)-α antibody preparation known to be less immunogenic than infliximab (IFX) or adalimumab. Few reports on GLM in pediatric patients with ulcerative colitis (UC) are available. This study aimed to review the long-term durability and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokita, Kazuhide, Shimizu, Hirotaka, Takeuchi, Ichiro, Shimizu, Toshiaki, Arai, Katsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679302/ https://www.ncbi.nlm.nih.gov/pubmed/36451693 http://dx.doi.org/10.5223/pghn.2022.25.6.461

Ejemplares similares

Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan
por: Shimizu, Hirotaka, et al.
Publicado: (2021)

Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience
por: Ito, Natsuki, et al.
Publicado: (2021)

Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis
por: Kinoshita, Naohiko, et al.
Publicado: (2022)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Predictors of Small Bowel Transit Time for Capsule Endoscopy in Children with Inflammatory Bowel Disease
por: Oka, Itsuhiro, et al.
Publicado: (2023)

Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study
por: Usami, Masaaki, et al.
Publicado: (2022)

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
por: Nakamura, Shiro, et al.
Publicado: (2022)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
por: Yanagi, Tadahiro, et al.
Publicado: (2019)

Anxiety, Depression, and Quality of Life in Parents of Adolescents with Inflammatory Bowel Disease: A Longitudinal Study
por: Nomura, Satomi, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
por: Tawa, Hideki, et al.
Publicado: (2022)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Phenotypic characteristics of pediatric inflammatory bowel disease in Japan: results from a multicenter registry
por: Arai, Katsuhiro, et al.
Publicado: (2020)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
por: Iborra, Marisa, et al.
Publicado: (2020)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
por: Perrig, Kathrin, et al.
Publicado: (2022)

Pediatric patient with eosinophilic esophagitis and pollen-food allergy syndrome
por: Irahara, Makoto, et al.
Publicado: (2020)

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
por: Gibson, Peter R, et al.
Publicado: (2016)

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2019)

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
por: Rutgeerts, P., et al.
Publicado: (2015)

Hepatic and Skeletal Muscle Autophagy Marker Levels in Rat Models of Prenatal and Postnatal Protein Restriction
por: Santosa, Irena, et al.
Publicado: (2023)

Novel TNFAIP3 microdeletion in a girl with infantile-onset inflammatory bowel disease complicated by a severe perianal lesion
por: Taniguchi, Kosuke, et al.
Publicado: (2021)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report
por: Alhalabi, Marouf M., et al.
Publicado: (2022)

Management of elderly ulcerative colitis in Japan
por: Higashiyama, Masaaki, et al.
Publicado: (2019)

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan
por: Ishige, Takashi, et al.
Publicado: (2023)

Skeletal Muscle Insulin Resistance in a Novel Fetal Growth Restriction Model
por: Tokita, Kazuhide, et al.
Publicado: (2023)

Correction to: Expert consensus on vaccination in patients with inflammatory bowel disease in Japan
por: Ishige, Takashi, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9clkd12lq47hd787tt1pod5pie